Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer
2018-004835-56Phase 2Active
- Sponsor
- GEMCAD
- Start
- Jun 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in rectal cancer and locally advanced rectal cancer (LARC), sponsored by GEMCAD. Primary endpoint: Pathological complete response (pCR) rate. Started Jun 2019; status: active.
02
Drugs
durvalumab
03
Conditions
rectal cancerlocally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on 2018-004835-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004835-56.